Advanced Filters
noise

Lexington, Kentucky Clinical Trials

A listing of Lexington, Kentucky clinical trials actively recruiting patient volunteers.

Found 216 clinical trials
F Francis Farhadi, MD, PhD

Spinal Cord Injury Neuroprotection With Glyburide

To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.

18 - 80 years of age All Phase 1
M Michael T Pulley

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

ME&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME&MG contains digital active tests for the assessment of ptosis, …

18 - 60 years of age All Phase N/A

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

18 years of age All Phase 1
A Austin Stone, MD, PhD

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at …

25 - 50 years of age All Phase N/A
M Matt Thomas, PhD

Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women

This is a randomized, parallel two-arm clinical trial design to study the efficacy of time-restricted feeding on metabolic risk in postmenopausal women, who may be particularly vulnerable to disruption of circadian eating rhythms and the associated metabolic dysfunction. It is hypothesized that time-restricted feeding will improve insulin sensitivity, glucose tolerance, …

45 - 65 years of age Female Phase N/A
C Christal L Badour, PhD

Healthy Recovery After Trauma Study

Mental contamination-an internal experience of dirtiness evoked in the absence of physical contact with an external source-has been linked to the development and maintenance of posttraumatic stress disorder (PTSD) following exposure to sexual abuse or assault (Adams et al., 2014; Badour et al., 2013; Brake et al., 2017). Mental contamination …

18 years of age All Phase N/A
Z Zin W. Myint

Pembro With Radiation With or Without Olaparib

This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.

18 years of age Male Phase 2
Y Yvonne Taul

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (1/28) (heterozygotes) and usual UGT metabolizers (1/1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual …

18 years of age All Phase N/A
E Eric Johnson, PharmD

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

18 - 90 years of age All Phase 2
L Lilli Neal

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

18 years of age All Phase 1

Simplify language using AI